Description
A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects With Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma.
Location: REDI (East Bay)
Please contact James Nasman NasmanJ@sutterhealth.org about MAGNIFY
View study details on ClinicalTrials.gov
Principal Investigator
Recruitment Status
Active, Recruiting
Please note that trial statuses change frequently,
for the most up to date information regarding REDI's enrolling studies; please
contact the research department at 510-204-4155.
Funder
Celgene Corporation
Start Date
December 23, 2014